M
Mengshi Zhou
Researcher at Case Western Reserve University
Publications - 5
Citations - 141
Mengshi Zhou is an academic researcher from Case Western Reserve University. The author has contributed to research in topics: Infliximab & Etanercept. The author has an hindex of 4, co-authored 5 publications receiving 61 citations. Previous affiliations of Mengshi Zhou include St. Cloud State University.
Papers
More filters
Journal ArticleDOI
Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
TL;DR: This study identifies a subset of patients in whom systemic inflammation contributes to risk for AD through a pathological mechanism involving TNF and who therefore may benefit from treatment with a TNF blocking agent.
Journal ArticleDOI
Combining phenome-driven drug-target interaction prediction with patients' electronic health records-based clinical corroboration toward drug discovery.
TL;DR: An integrated approach that seamlessly combines computational DTI prediction and large-scale patients’ EHRs-based clinical corroboration has high potential in rapidly identifying novel drug targets and drug candidates for complex diseases.
Journal ArticleDOI
A Drug-Side Effect Context-Sensitive Network approach for drug target prediction.
Mengshi Zhou,Yang Chen,Rong Xu +2 more
TL;DR: A context-sensitive network (CSN) model for DTI prediction by modeling the context-specific inter-relationships among drugs and side effects, has a high potential in drug target prediction.
Journal ArticleDOI
Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses.
Mengshi Zhou,Mengshi Zhou,QuanQiu Wang,Chunlei Zheng,A. John Rush,A. John Rush,A. John Rush,Nora D. Volkow,Rong Xu +8 more
TL;DR: In this paper, an integrated drug repurposing strategy that combines computational prediction, clinical corroboration using electronic health records (EHRs) of over 72.9 million patients and mechanisms of action analysis was presented.
Posted ContentDOI
Tumor Necrosis Factor (TNF) Blocking Agents are Associated with Lower Risk for Alzheimer’s Disease in Patients with Rheumatoid Arthritis and Psoriasis
TL;DR: This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent reduced risk for Alzheimer9s disease (AD) in patients with rheumatoid arthritis, psoriasis, and other inflammatory diseases which are mediated in part by TNF and for which a TNF blocker is an approved treatment.